Specialties

SGLT2 inhibitors compared to DPP-4 inhibitors: which showed a favorable effect on MACE? 

Weight loss is a significant lifestyle modification that can affect both diabetes and the risk for some cancers.

Finerenone, which treats CKD, may also help to reduce cardiac failure in type 2. 

The CARDIA study explored the link to the decline in cognitive abilities in diseases like Alzheimer's and Parkinson's in middle-aged populations.

Cardiovascular events and diabetes go hand in hand, but what if there’s already a drug out there to lower the risk of those events?  

A study based on the Look AHEAD trial examined how weight loss and physical activity impact the risk of HF, MI, and T2DM.

Study finds patients with a higher degree of retinopathy severity had worse cardiovascular outcomes. 

A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.

A patient, 62 years of age, with type 2 diabetes, obesity, and an intellectual disability disorder, had been a patient at our clinic for over ten years. Treatment included metformin and insulin. He met regularly with his endocrinologist and diabetes educator. He often spoke about wanting to lose weight....

Less than 20% of children with type 1 diabetes attain the target glycated hemoglobin level of less than 7% recommended by the American Diabetes Association.